Here, we investigated the open question of whether and how mutations in splicing factors such as RBM10 contribute to lung cancer pathogenesis or modulate sensitivity to oncoprotein-targeted kinase inhibitor therapy. The gene discussed is RBM10; the disease is lung carcinoma.